15
Participants
Start Date
October 30, 2018
Primary Completion Date
February 11, 2021
Study Completion Date
February 11, 2021
Aprepitant 125 mg
Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
Fosaprepitant 115 MG
Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
Dexamethasone
Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy
Ondansetron 16 MG
Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
Jacobi Medical Center, The Bronx
Montefiore Medical Center, The Bronx
Collaborators (1)
Jacobi Medical Center
OTHER
Albert Einstein College of Medicine
OTHER